Zenas BioPharma (USA) LLC
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2020-01-01
- Employees
- 51
- Market Cap
- -
- Website
- https://zenasbio.com
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Zenas BioPharma (USA), LLC
- Target Recruit Count
- 93
- Registration Number
- NCT06564311
- Locations
- 🇺🇸
North Central Neurology, Cullman, Alabama, United States
🇨🇿General University Hospital Praha, Praha, Czechia
🇩🇰Aalborg Universitetshospital, Aalborg, Denmark
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Zenas BioPharma (USA), LLC
- Target Recruit Count
- 190
- Registration Number
- NCT06559163
- Locations
- 🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸Penn State - Hershey Medical Center, Hershey, Pennsylvania, United States
🇧🇪CHU de Liege, Liege, Belgium
A Safety and Pharmacokinetics Study of ZB004 in Healthy Participants
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Zenas BioPharma (USA), LLC
- Target Recruit Count
- 40
- Registration Number
- NCT05794516
- Locations
- 🇳🇿
NZCR New Zealand Clinical Research, Christchurch, New Zealand
A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)
- Conditions
- Warm Autoimmune Hemolytic Anemia
- Interventions
- Other: Placebo
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Zenas BioPharma (USA), LLC
- Target Recruit Count
- 134
- Registration Number
- NCT05786573
- Locations
- 🇮🇹
Fondazione IRCCS CÃ Granda Ospedale Maggiore Policlinico, Milano, Italy
🇵🇱Copernicus PL Sp. z o.o. Wojewodzkie Centrum Onkologii, Gdansk, Pomorskie, Poland
🇪🇸Hospital Universitario de Burgos, Burgos, Spain
Study of ZB001 in Chinese Patients With Thyroid Eye Disease
- Conditions
- Thyroid Eye Disease
- Interventions
- Drug: ZB001 for injection
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Zenas BioPharma (USA), LLC
- Target Recruit Count
- 17
- Registration Number
- NCT05776121
- Locations
- 🇨🇳
Beijing Tongren Hospital, CMU, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, China
A Phase 3 Study of Obexelimab in Patients with IgG4-Related Disease
- Conditions
- IgG4 Related Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Zenas BioPharma (USA), LLC
- Target Recruit Count
- 194
- Registration Number
- NCT05662241
- Locations
- 🇦🇷
Consultora Integral de Salud Centro Médico Privado, Córdoba, Argentina
🇨🇦Artus Health Centre, Vancouver, British Columbia, Canada
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
A Study to Evaluate Safety and Pharmacokinetics of ZB002 in Healthy Participants and Participants With Rheumatoid Arthritis
- Conditions
- Healthy VolunteersRheumatoid Arthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Zenas BioPharma (USA), LLC
- Target Recruit Count
- 72
- Registration Number
- NCT05638854
- Locations
- 🇦🇺
Veritus Research, Melbourne, Australia
🇳🇿NZCR New Zealand Clinical Research, Christchurch, New Zealand
A Safety, Tolerability and Pharmacokinetics Study of ZB001 in Healthy Subjects
- Conditions
- Healthy Volunteers
- Interventions
- Drug: ZB001 for injection
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Zenas BioPharma (USA), LLC
- Target Recruit Count
- 24
- Registration Number
- NCT05542303
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, China